Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting

Abstract

Chimeric antigen receptors (CARs) and synthetic Notch (synNotch) receptors are engineered cell-surface receptors that sense a target antigen and respond by activating T cell receptor signaling or a customized gene program, respectively. Here, to expand the targeting capabilities of these receptors, we develop “universal” receptor systems for which receptor specificity can be directed post-translationally via covalent attachment of a co-administered antibody bearing a benzylguanine (BG) motif. A SNAPtag self-labeling enzyme is genetically fused to the receptor and reacts with BG-conjugated antibodies for covalent assembly, programming antigen recognition. We demonstrate that activation of SNAP-CAR and SNAP-synNotch receptors can be successfully targeted by clinically relevant BG-conjugated antibodies, including anti-tumor activity of SNAP-CAR T cells in vivo in a human tumor xenograft mouse model. Finally, we develop a mathematical model to better define the parameters affecting universal receptor signaling. SNAP receptors provide a powerful strategy to post-translationally reprogram the targeting specificity of engineered cells.

Document Details

Document Type
Pub Defense Publication
Publication Date
May 09, 2023
Source ID
10.1038/s41467-023-37863-5

Entities

People

  • Adam A. Butchy
  • Alexander Deiters
  • Avani Parikh
  • Elisa Ruffo
  • Eric L. Adams
  • Jason Lohmueller
  • Michael Kvorjak
  • Nataša Miškov-Živanov
  • Olivera J. Finn
  • Victor So
  • Yaniv Tivon

Organizations

  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases
  • National Cancer Institute
  • National Institute of General Medical Sciences
  • United States Department of Defense
  • United States Department of Health and Human Services

Tags

Fields of Study

  • Biology

Readers

  • Molecular and Cellular Biochemistry
  • Oncology (Cancer Research).

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech